Last updated: 2026-02-24 16:52:02 ET
Starting in 2027, the Danish pharma firm will sell its weight-loss and diabetes drugs for $675 per month.
The cuts aim to make the drugs more accessible to insured patients, particularly people with high-deductible health plans or co-insurance benefit desi...
Shares of Novo Nordisk and rival Eli Lilly fell on Tuesday after a report said price cuts are coming for popular weight-loss drugs.
Novo Nordisk’s study showing a new drug wasn’t as good as a rival’s led one sell-side analyst to downgrade the stock for the first time in five ...
These are the stocks posting the largest moves in premarket trading.
Novo Nordisk stock fell 15% Monday after it said its next-generation weight loss drug didn't meet its primary target.
Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug in development didn�...
